Veraxa Biotech names Christoph Erkel chief scientific officer, succeeding Rick Austin

• Veraxa Biotech named Christoph Erkel chief scientific officer, effective immediately, to drive development of its BiTAC platform and oncology pipeline.
• Erkel was previously vice president of R&D; his background includes 20 years in antibody therapeutics spanning discovery through IND submission.
• He previously led immuno-oncology programs at MorphoSys, including conditionally active T-cell engagers, following roles at Sloning BioTechnology.
• Rick Austin will exit the company following a transition period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230700OMX_____CNEWS_EN_GNW1001214113_en) on July 23, 2026, and is solely responsible for the information contained therein.